Why AVBP fell 20.8% on Oct 26 2026: phase 1 data
AVBP-20.8%on Mon Oct 26 2026
ArriVent BioPharma, Inc. Common Stock was down 20.8% on the day at $16.63, ranked #7 on 27.0× its usual five-minute volume, when TapeRank recorded this drop at 09:33 ET during regular hours.
THE DAY ON THE LIST · 1 EVENT
- 09:33 ETMOVER · REGULAR
$16.63 · ▼ 20.8% ON THE DAY · 27.0× 5M RVOL · RANK #7
STRETCHEDCONFIDENCE4/5AVBP is down 14.5%, including a sharp 6.75% five-minute drop, after reporting initial Phase 1 ARR-217 data with a 44.8% response rate at one dose in late-line colorectal cancer. The clinical result is concrete but early and limited to an initial dataset, so the magnitude and abruptness of the selloff indicate the market is discounting risks or details beyond the headline.
WHYA 14.5% decline and 6.75% five-minute flush is a large move relative to promising but preliminary Phase 1 data showing a 44.8% response rate at one dose.ANALYZED 09:31 ET · 1 MIN AGO · OPENAI/GPT-5.6-LUNATHE ROW AND SESSION LEVELS AT 09:33 ET
LAST16.63DAY▼ 20.8%5 MIN▼ 8.35%5M RVOL27.0×5M $VOL$2.7MFLOAT*49.3MRANK#7SESSIONREGULARVWAP20.79HOD26.46LOD16.60OR HIGH18.16OR LOW16.60PREV CLOSE21.00PM HIGH26.46PM LOW17.49GAP▼ 13.62%* FLOAT IS SHARES OUTSTANDING; TRUE FREE FLOAT IS NOT AVAILABLE
THE SESSION
- 09:30 ETOpened at $18.14, -13.6% on the previous close of $21.00
- 09:30 ETRegular-session high, $18.16
- 10:34 ETRegular-session low, $14.78
- 15:59 ETLast trade of the regular session, $15.31, -27.1% on the previous close of $21.00
- Volume: 5.3M shares in regular hours, 197K before the open
AVBP opened at $18.14, briefly reached $18.16, then fell to $14.78 by 10:34 ET before recovering to finish the regular session at $15.31, still below the previous close of $21.00. TapeRank tied the move to ArriVent’s initial Phase 1 ARR-217 data, which showed a 44.8% response rate at one dose in late-line colorectal cancer, alongside a 06:00 ET 8-K disclosure; its read described the early clinical result as concrete but limited and the selloff as stretched. The stock had no halts and traded 5.3M shares during regular hours.
WRITTEN MON OCT 26 2026 16:00 ET BY OPENAI/GPT-5.6-LUNA FROM THE FACTS ON THIS PAGE
FILINGS AND NEWS · 24H BEFORE THE MOVE
- 06:00 ET8-K — Regulation FD Disclosure; Other Events; Financial Statements and ExhibitsSEC 8-K
- SUN 13:59 ETArriVent Announced Sunday, Initial Phase 1 Data For CDH17-Targeted ADC ARR-217 In Gastrointestinal Cancers At ESMO, Demonstrating 44.8% Objective Response Rate At 6mg/kg Dose In Late-Line Colorectal Cancer PatientsBenzinga
On the tape right now
WHERE THE LIST STOODWED NOV 4 2026 · 13:49 ETRECORDED LIVE · 742 QUALIFY
Open the full list